BAB 7

KESIMPULAN DAN SARAN

7.1 Kesimpulan

Berdasarkan hasil penelitian yang diperoleh, maka dapat disimpulkan bahwa :

1. Terdapat peningkatan NO pada pemberian ekstrak daun kersen (Muntingia calabura L.) terhadap tikus putih (Rattus norvegicus).
2. Peningkatan NO tertinggi didapatkan pada pemberian ekstrak etanol daun kersen (Muntingia calabura L.) konsentrasi 200 mg/mL.
3. Peningkatan NO pada pemberian ekstrak daun kersen (Muntingia calabura L.) bersifat linier.
4. Terdapat perbedaan bermakna kadar NO pada pemberian ekstrak daun kersen (Muntingia calabura L.) pada konsentrasi 50, 100, dan 200 mg/mL.

7.2 Saran

Berdasarkan hasil penelitian yang diperoleh, maka dapat disarankan bahwa :.

1. Rentang konsentrasi ekstrak daun kersen (Muntingia calabura L.) lebih dipeluas agar mendapat konsentrasi terendah yang dapat meningkatkan NO.
2. Melakukan penelitan dengan mengukur kadar NO dalam darah setelah pemberian ekstrak daun kersen (Muntingia calabura L.).

DAFTAR PUSTAKA

1. Hermann M1, Flammer A LT. NItric Oxide in Hypertension. 2006; Available from: https://www.ncbi.nlm.nih.gov/pubmed/17170603
2. Duarte J, Francisco V, Perez-Vizcaino F. Modulation of nitric oxide by flavonoids. Food Funct. 2014 Aug;5(8):1653–68.
3. Kemenkes.RI. Pusdatin Hipertensi. Infodatin [Internet]. 2014;(Hipertensi):1–7. Available from: https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjIzfDJsYPKAhVSA44KHUmSDasQFggZMAA&url=http://www.depkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-hipertensi.pdf&usg=AFQjCNHWLiHieCeL1Ksg4Tr_yx
4. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS) 2013. Lap Nas 2013. 2013;1–384.
5. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(SUPPL. 1):193–201.
6. Evora PRB, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets. 2012 Aug;13(9):1207–14.
7. Manuchair E. Pharmacodynamic Basis of Herbal Medicine. CRC PRESS; 2010.
8. R. S, S. I, S. P, N. D, U. G, A. Z, et al. Phytochemical Analysis of Muntingia calabura Extracts Possessing Anti-Microbial and Anti-Fouling Activities. Int J Pharmacogn Phytochem Res [Internet]. 2017;9(6). Available from: http://www.myresearchjournals.com/index.php/Phyto/article/view/8186
9. Ignarro LJ& BF. Nitric Oxide: Biology and Pathobiology. third edit. Louis J. Ignarro BF, editor. Academic Press Elsevier; 2017.
10. Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol. 2011 Jun;300(6):R1288-95.
11. Stuehr D, Pou S, Rosen GM. Oxygen reduction by nitric-

oxide synthases. J Biol Chem. 2001 May;276(18):14533–6.
12. Förstermann U, Sessa WC. Nitric oxide synthases: Regulation and function. Eur Heart J. 2012;33(7):829–37.
13. Moens AL, Kass DA. Tetrahydrobiopterin and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2006;26(11):2439–44.
14. Piazza M, Guillemette JG, Dieckmann T. Dynamics of Nitric Oxide Synthase–Calmodulin Interactions at Physiological Calcium Concentrations. Biochemistry [Internet]. 2015 Mar 24;54(11):1989–2000. Available from: https://doi.org/10.1021/bi501353s
15. Zhou L, Zhu D-Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric oxide Biol Chem. 2009 Jun;20(4):223–30.
16. Toda N, Ayajiki K, Okamura T. Control of systemic and pulmonary blood pressure by nitric oxide formed through neuronal nitric oxide synthase. J Hypertens. 2009 Oct;27(10):1929–40.
17. Medicina ES De, Nacional IP, México DF. NIH Public Access. 2011;49(3):307–16.
18. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol [Internet]. 2010;88(6):1157–62. Available from: http://www.jleukbio.org/cgi/doi/10.1189/jlb.0310149
19. Durán WN, Breslin JW, Sánchez FA. The NO cascade, eNOS location, and microvascular permeability. Cardiovasc Res. 2010;87(2):254–61.
20. Averna M, Stifanese R, De Tullio R, Passalacqua M, Salamino F, Pontremoli S, et al. Functional role of HSP90 complexes with endothelial nitric-oxide synthase (eNOS) and calpain on nitric oxide generation in endothelial cells. J Biol Chem. 2008;283(43):29069–76.
21. Wales J. Allosteric Regulation of Soluble Guanylyl Cyclase : The Nitric Oxide Receptor In the Graduate College. 2018;
22. Sowa G, Pypaert M, Sessa WC. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc Natl Acad Sci U S A. 2001 Nov;98(24):14072–7.
23. Tamas R. The Biology of Subcellular Nitric Oxide. Springer; 2012.
24. Vivian F. Cardiovascular Endocrinology: Shared Pathways

and Clinical Crossroads. humana press; 2008.
25. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001 Sep;293(5539):2449–52.
26. Evgenov O V, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov [Internet]. 2006 Sep 1;5:755. Available from: http://dx.doi.org/10.1038/nrd2038
27. Esplugues J V. NO as a signalling molecule in the nervous system. Br J Pharmacol. 2002;135(5):1079–95.
28. Costa ED, Rezende BA, Cortes SF, Lemos VS. Neuronal nitric oxide synthase in vascular physiology and diseases. Front Physiol. 2016;7(JUN):1–8.
29. Pacher P, Beckman JS, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev [Internet]. 2007;87(1):315–424. Available from: http://physrev.physiology.org/cgi/doi/10.1152/physrev.00029.2006
30. Kumar A, Chen S-H, Kadiiska MB, Hong J-S, Zielonka J, Kalyanaraman B, et al. Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. Free Radic Biol Med. 2014 Aug;73:51–9.
31. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov [Internet]. 2011;10(4):277–91. Available from: http://dx.doi.org/10.1038/nrd3358
32. Modi A, Morou-Bermudez E, Vergara J, Patel RP, Nichols A, Joshipura K. Validation of two point-of-care tests against standard lab measures of NO in saliva and in serum. Nitric oxide Biol Chem. 2017 Apr;64:16–21.
33. Luiking Y, Engelen M, Deutz N. Regulation of nitric oxide production in health and disease. Curr Opin Clin Nutr Metab Care [Internet]. 2010;13(1):97–104. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2953417/
34. K. LT. Edible Medicinal And Non Medicinal Plants. third. Springer; 2011.
35. Janick J& REP. The Encyclopedia of Fruit and Nuts

[Internet]. CAB International; 2008. Available from: https://books.google.co.id/books?id=cjHCoMQNkcgC&pg=PA348&dq=muntingia+calabura+l&hl=id&sa=X&ved=0ahUKEwiSvuedjvbaAhWGvo8KHb6fBBwQ6AEIOzAD#v=onepage&q=muntingia calabura l&f=false

36. Singh A. Herbalism, Phytochemistry and Ethnopharmacology [Internet]. CRC PRESS; Available from: https://books.google.co.id/books?id=CIDRBQAAQBAJ&pg=PA36&dq=Phytochemical+definition&hl=id&sa=X&ved=0ahUKEwj6_Z3dj_baAhUFOY8KHTTzAe8Q6AEINTAC#v=onepage&q=Phytochemical definition&f=false
37. Michael Heinrich, Joanne Barnes, Simon ibbons EMW. Fundamentals of Pharmacognosy and Phytotherapy. second. Elsevier; 2004.
38. Mukhriani. Ekstraksi, pemisahan senyawa, dan identifikasi senyawa aktif. J Kesehat. 2014;VII(2):361–7.
39. Armitage D. "Rattus norvegicus" (On-line), Animal Diversity [Internet]. Michigan University. 2004. Available from: http://animaldiversity.org/accounts/Rattus_norvegicus/
40. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317–27.
41. Hilas O, Ezzo D. Nebivolol (Bystolic), a Novel Beta Blocker for Hypertension. Vol. 34, P & T : a peer-reviewed journal for formulary management. 2009. 188-192 p.
42. Weiss R. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation. Vasc Health Risk Manag [Internet]. 2006/09/. 2006 Sep;2(3):303–8. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17326335
43. Shih C-D, Chen J-J, Lee H-H. Activation of Nitric Oxide Signaling Pathway Mediates Hypotensive Effect of Muntingia calabura L. (Tiliaceae) Leaf Extract. Am J Chin Med [Internet]. 2006 Jan 1;34(05):857–72. Available from: https://doi.org/10.1142/S0192415X0600434X
44. Evora PR, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets [Internet]. 2012;13(9):1207–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22716077
45. Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in

Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. US Dep Heal Hum Serv [Internet]. 2005;(July):1–27. Available from: http://www.fda.gov/downloads/Drugs/Guidance/UCM078932.pdf

46. World Medical Association. World Medical Association Declaration of Helsinki. Bull world Heal Organ [Internet]. 2001;79(4):373–4. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2566407&tool=pmcentrez&rendertype=abstract
47. Sibi G, Naveen R, Dhananjaya K, Ravikumar KR, Mallesha H. Potential use of Muntingia calabura L . extracts against human and plant pathogens. 2012;4(1).
48. Zakaria ZA, Mohamed AM, Jamil NSM, Rofiee MS, Hussain MK, Sulaiman MR, et al. In vitro antiproliferative and antioxidant activities of the extracts of Muntingia calabura leaves. Am J Chin Med. 2011;39(1):183–200.
49. Benito S, Lopez D, Saiz MP, Buxaderas S, Sanchez J, Puig-Parellada P, et al. A flavonoid-rich diet increases nitric oxide production in rat aorta. Br J Pharmacol. 2002 Feb;135(4):910–6.
50. Clark JL, Zahradka P, Taylor CG. Efficacy of flavonoids in the management of high blood pressure. Nutr Rev. 2015 Dec;73(12):799–822.